Mainz Biomed reports positive interim results from CRC screening campaign

Mainz Biomed announced positive interim results from its CRC screening campaign through its BGM partnership with Zoller-Kipper GmbH, part of the Zoller group with more than 2,600 employees. The partnership was launched in April 2023, when Zoller-Kipper selected ColoAlert, Mainz Biomed’s highly efficacious and easy-to-use screening test for CRC, for its corporate health program. “We are delighted that nearly half of Zoller-Kipper’s employees in Germany have embraced our CRC screening campaign. The promising interim results further fuel our commitment to expanding the accessibility of ColoAlert(R) and ensuring as many people as possible can benefit from potentially lifesaving screening,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Colorectal cancer is the second most lethal form of cancer, and early detection is paramount in enhancing treatment options and survival rates. We are immensely grateful to Zoller-Kipper for their invaluable collaboration and for having such a progressive approach to employee welfare. This initiative sets a very strong precedent for our future collaborations with companies across Germany and Europe.”